Page 22 - 《中国药房》2024年9期
P. 22

·药学研究·


          马里苷对酒精性脂肪肝的保护作用及机制
                                                                         Δ

                           2
                                   1
                                                   1
                                           1
                 1*
                                                           2 #
          牛广豪 ,徐俊驰 ,顾利青 ,许 英 ,顾宇人 ,宋华峰 [1.苏州市第五人民医院(苏州大学附属传染病医院)临
          床试验机构办公室,江苏 苏州 215000;2.苏州市第五人民医院(苏州大学附属传染病医院)检验中心,江苏
          苏州 215000]
          中图分类号  R965      文献标志码  A      文章编号  1001-0408(2024)09-1044-06
          DOI  10.6039/j.issn.1001-0408.2024.09.04


          摘   要  目的  探究马里苷对酒精性脂肪肝(AFL)的保护作用及可能机制。方法  以高度白酒灌胃建立小鼠AFL模型,将小鼠按
          体重随机分为正常对照组(n=9,0.5%羧甲基纤维素钠溶液)、模型组(n=10,0.5%羧甲基纤维素钠溶液)和马里苷75、150 mg/kg
          组(n=9);每天灌胃给药 1 次,连续 30 d。末次给药后,测定小鼠肝组织中甘油三酯(TG)、丙二醛(MDA)和超氧化物歧化酶
         (SOD)水平,观察其肝组织病理形态学变化,测定其肝组织中过氧化物酶体增殖物激活受体 α(PPARα)、肉碱棕榈酰转移酶 1
         (CPT-1)和二脂酰甘油酰基转移酶(DGAT)蛋白表达水平。以乙醇诱导结合硫酸亚铁和油酸建立大鼠BRL肝细胞损伤模型,以3、
          6、12 μmol/L 马里苷干预 24 h,观察肝细胞的脂滴分布,测定细胞中 TG、MDA、SOD 水平及 PPARα、CPT-1、DGAT 蛋白表达;经
          MK886(PPARα抑制剂,10 μmol/L)预处理后,将造模肝细胞给予12 μmol/L马里苷干预24 h,测定细胞中上述蛋白表达。结果  动
          物实验中,与模型组比较,马里苷75、150 mg/kg组小鼠肝脏脂肪变性程度显著减轻,TG、MDA水平和DGAT蛋白表达水平显著降
          低(P<0.05 或 P<0.01),SOD 水平及 PPARα、CPT-1 蛋白水平表达水平显著升高(P<0.05 或 P<0.01)。细胞实验中,3、6、12
          μmol/L马里苷作用后可显著减少乙醇诱导肝细胞中脂质堆积,降低细胞中TG、MDA水平和DGAT蛋白表达水平(P<0.05或P<
          0.01),升高细胞中SOD水平及PPARα、CPT-1蛋白表达水平(P<0.05或P<0.01),且在MK886预处理后马里苷对PPARα、CPT-1
          和DGAT蛋白表达的影响消失。结论  马里苷对AFL具有保护作用,其作用机制可能与抑制氧化应激损伤、改善PPARα介导的脂
          质代谢信号通路有关。
          关键词  马里苷;酒精性脂肪肝;氧化应激;脂质代谢;过氧化物酶体增殖物激活受体α

          Protective effect of marein against alcoholic fatty liver and its mechanism
                                               1
                                   2
                        1
                                                                                    2
          NIU Guanghao ,XU Junchi ,GU Liqing ,XU Ying ,GU Yuren ,SONG Huafeng [1.  Clinical  Trial  Institution
                                                                    1
                                                         1
          Office,  the  Fifth  People’s  Hospital  of  Suzhou (the  Affiliated  Infectious  Diseases  Hospital  of  Soochow
          University),  Jiangsu  Suzhou  215000,  China;2.  Inspection  Center,  the  Fifth  People’s  Hospital  of  Suzhou (the
          Affiliated Infectious Diseases Hospital of Soochow University), Jiangsu Suzhou 215000, China]
          ABSTRACT    OBJECTIVE  To  explore  the  protective  effect  of  marein  against  alcoholic  fatty  liver (AFL)  and  its  potential
          mechanisms.  METHODS  AFL  mice  model  was  established  with  strong  wine  by  gavage.  The  mice  were  randomly  divided  into
          normal  control  group (n=9,  0.5%  sodium  carboxymethyl  cellulose  solution),  model  group (n=10,  0.5%  sodium  carboxymethyl
          cellulose  solution)  and  marein  75  and  150  mg/kg  groups (n=9).  Mice  were  given  relevant  medicine  intragastrically,  once  a  day,
          for  consecutive  30  days.  After  the  last  medication,  the  levels  of  triglyceride (TG),  malondialdehyde (MDA),  and  superoxide
          dismutase (SOD) in liver tissue were determined, and hepatic histopathological changes of liver tissue were observed; the protein
          expression  levels  of  peroxisome  proliferator-activated  receptor  α (PPARα),  carnitine  palmitoyltransferase-1 (CPT-1),  and
          diacylglycerol  acyltransferase (DGAT)  were  determined  in  liver  tissue.  BRL  hepatocytes  injury  model  was  induced  by  ethanol
          combined with ferrous sulfate and oleic acid; after treatment with 3, 6 and 12 μmol/L of marein for 24 h, the distribution of lipid
          droplets,  the  levels  of TG,  MDA  and  SOD  and  protein  expressions  of  PPARα,  CPT-1  and  DGAT  in  hepatocytes  were  examined.
                                                              After pretreatment with MK886 (PPARα inhibitor, 10 μmol/L),
              Δ 基金项目 国家自然科学基金青年项目(No.81900577);苏州市
                                                              modeled  hepatocytes  were  treated  with  12  μmol/L  of  marein
          姑苏卫生人才科研项目(No.GSWS2022089);苏州市科技计划-医工结
                                                              for  24  h,  and  the  protein  expressions  of  PPARα,  CPT-1  and
          合协同创新研究项目(No.SLJ2022022)
             *第一作者 主管药师,硕士。研究方向:临床药理学。E-mail:                 DGAT  were  determined.  RESULTS  As  the  results  showed  in
          ngh2367@suda.edu.cn                                 vivo,  compared  with  the  model  group,  after  treatment  with  75
              # 通信作者 副主任技师,硕士。研究方向:传染性疾病病原学诊                  and  150  mg/kg  of  marein,  the  degree  of  steatosis  was
          断及临床药物耐药。E-mail:506650847@qq.com                    significantly  reduced,  and  the  levels  of  TG  and  MDA  and


          · 1044 ·    China Pharmacy  2024 Vol. 35  No. 9                              中国药房  2024年第35卷第9期
   17   18   19   20   21   22   23   24   25   26   27